{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:19:28Z","timestamp":1794071968204,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["KK.01.1.1.02.0021"],"award-info":[{"award-number":["KK.01.1.1.02.0021"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Croatian Science Foundation","doi-asserted-by":"publisher","award":["HRZZ-UIP-2017-05-3949"],"award-info":[{"award-number":["HRZZ-UIP-2017-05-3949"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004488","name":"Croatian Science Foundation","doi-asserted-by":"publisher","award":["HRZZ-DOK-2021-02-7922"],"award-info":[{"award-number":["HRZZ-DOK-2021-02-7922"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.heliyon.2024.e34066","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T22:48:06Z","timestamp":1720046886000},"page":"e34066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Development and validation of stability-indicating method of etrasimod by HPLC\/DAD\/MS\/MS technique with greenness profiling"],"prefix":"10.1016","volume":"10","author":[{"given":"Jelena","family":"Kova\u010di\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Amid\u017ei\u0107 Klari\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nik\u0161a","family":"Turk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017deljko","family":"Krznari\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-697X","authenticated-orcid":false,"given":"Ana","family":"Mornar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e34066_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/ecco-jcc\/jjaa146","article-title":"Prevalence and Duration of gastrointestinal symptoms before diagnosis of inflammatory bowel disease and predictors of timely specialist review: a population-based study","volume":"15","author":"Blackwell","year":"2021","journal-title":"J. Crohns Colitis"},{"issue":"10383","key":"10.1016\/j.heliyon.2024.e34066_bib2","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e34066_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1025375","article-title":"Prognostication in inflammatory bowel disease","volume":"9","author":"Spencer","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.heliyon.2024.e34066_bib4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/MEG.0000000000001730","article-title":"Small molecule drugs in the treatment of inflammatory bowel diseases: which one, when and why? - a systematic review","volume":"32","author":"Lucaciu","year":"2020","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e34066_bib5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3390\/ph14070637","article-title":"Small molecule drugs in inflammatory bowel diseases","volume":"14","author":"Ben Ghezala","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.heliyon.2024.e34066_bib6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fphar.2019.00212","article-title":"Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists","volume":"10","author":"P\u00e9rez-Jeldres","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e34066_bib7","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.3390\/biomedicines10071735","article-title":"Sphingosine 1-phosphate modulation in inflammatory bowel diseases: keeping lymphocytes out of the intestine","volume":"10","author":"Dal Buono","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.heliyon.2024.e34066_bib8","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.3390\/jcm12155014","article-title":"Efficacy and safety of S1P1 receptor modulator drugs for patients with moderate-to-severe ulcerative colitis","volume":"12","author":"Bencardino","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.heliyon.2024.e34066_bib9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/apt.16741","article-title":"Review article: the sphingosine 1 phosphate\/sphingosine 1 phosphate receptor axis - a unique therapeutic target in inflammatory bowel disease","volume":"55","author":"Wang","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e34066_bib10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14712598.2020.1732919","article-title":"Modulation of sphingosine-1-phosphate in ulcerative colitis","volume":"20","author":"Argollo","year":"2020","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.heliyon.2024.e34066_bib11","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/10600280211041907","article-title":"Ozanimod: a first-in-class sphingosine 1-phosphate receptor modulator for the treatment of ulcerative colitis","volume":"56","author":"Choi","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e34066_bib12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3390\/ijms18040741","article-title":"Sphingosine-1-phosphate metabolism and its role in the development of inflammatory bowel disease","volume":"18","author":"Wollny","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.heliyon.2024.e34066_bib13","first-page":"312","article-title":"Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus","volume":"S1590\u20138658","author":"Olivera","year":"2024","journal-title":"Dig. Liver Dis."},{"issue":"2024","key":"10.1016\/j.heliyon.2024.e34066_bib14","first-page":"219","article-title":"FDA approvals in gastroenterology and hepatology","volume":"21","author":"Kotsiliti","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e34066_bib15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40265-024-01997-7","article-title":"Etrasimod: first approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2024.e34066_bib16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijpharm.2018.04.007","article-title":"Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: a comprehensive review","volume":"543","author":"Sengupta","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.heliyon.2024.e34066_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115880","article-title":"The quality of drugs and drug products \u2013 always guaranteed?","volume":"239","author":"Buschmann","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.heliyon.2024.e34066_bib21","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1039\/C8GC03875A","article-title":"Making the move towards modernized greener separations: introduction of the analytical method greenness score (AMGS) calculator","volume":"21","author":"Hicks","year":"2019","journal-title":"Green Chem."},{"key":"10.1016\/j.heliyon.2024.e34066_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trac.2012.03.013","article-title":"Analytical Eco-Scale for assessing the greenness of analytical procedures","volume":"37","author":"Ga\u0142uszka","year":"2012","journal-title":"TrAC, Trends Anal. Chem."},{"key":"10.1016\/j.heliyon.2024.e34066_bib23","doi-asserted-by":"crossref","first-page":"8657","DOI":"10.1039\/D1GC02318G","article-title":"Complementary green analytical procedure index (ComplexGAPI) and software","volume":"23","author":"P\u0142otka-Wasylka","year":"2021","journal-title":"Green Chem."},{"key":"10.1016\/j.heliyon.2024.e34066_bib24","doi-asserted-by":"crossref","first-page":"10076","DOI":"10.1021\/acs.analchem.0c01887","article-title":"AGREE-Analytical GREEnness metric approach and software","volume":"92","author":"Pena-Pereira","year":"2020","journal-title":"Anal. Chem."},{"key":"10.1016\/j.heliyon.2024.e34066_bib25","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3389\/fchem.2020.00726","article-title":"Computational approaches in preclinical studies on drug discovery and development","volume":"8","author":"Wu","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.heliyon.2024.e34066_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.813359","article-title":"Towards higher sensitivity of mass spectrometry: a perspective from the mass analyzers","volume":"9","author":"Li","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.heliyon.2024.e34066_bib27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/cpdd.1255","article-title":"Disposition and mass balance of etrasimod in healthy subjects and in vitro determination of the enzymes responsible for its oxidative metabolism","volume":"12","author":"Lee","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.heliyon.2024.e34066_bib28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/mas.21757","article-title":"Tandem mass spectrometry approaches for recognition of isomeric compounds mixtures","volume":"42","author":"Crotti","year":"2023","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.heliyon.2024.e34066_bib29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/separations10020069","article-title":"Green solid-phase (micro)extraction of andrographolides' from human plasma samples followed by UHPLC-DAD-QqQ-MS\/MS analysis","volume":"10","author":"Kova\u010di\u0107","year":"2023","journal-title":"Separations"},{"key":"10.1016\/j.heliyon.2024.e34066_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/acph-2023-0044","article-title":"Size exclusion chromatography as green support for forced degradation study of adalimumab","volume":"73","author":"Kova\u010di\u0107","year":"2023","journal-title":"Acta Pharm."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024100977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024100977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:51:11Z","timestamp":1778885471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024100977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2405844024100977"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34066","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of stability-indicating method of etrasimod by HPLC\/DAD\/MS\/MS technique with greenness profiling","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e34066"}}